...
Best performers will be invited to present at the DREAM conference with travel expenses covered by the Sage/DREAM organizers. We are working with high impact journals to ensure that the methodology developed by the best performer will be considered for publication under the challenge-assisted peer review format.
National Brain Tumor Society – DREAM Cancer Prediction Challenge
Click here to read the National Brain Tumor Society Press Release
Sponsored by the National Brain Tumor Society (NBTS), this Challenge aims to predictin vivo drug activity on glioblastoma tumors. The Challenge will be organized by Sage Bionetworks and DREAM, and jointly led by experts from the National Brain Tumor Society (NTBS), Columbia University and others. The Challenge will invite participants to predict the specific drugs and drug combinations that will elicit the strongest therapeutic response in mice orthotopically transplanted with human high grade gliomas, based on their baseline genomic characterization. Relevant data, including baseline GBM related molecular profiles from TCGA, molecular profiles of mouse xenografts for which drug activity will be inferred, and baseline drug response in GBM related lines, from the cancer cell line encyclopedia (CCLE), will be hosted on a compute platform along with the participants’ code for their models. This will allow teams to have credit for sharing their ideas and models thereby accelerating insights before publication. Existing data will be made publicly available to the research community for the assembly and interrogation of GBM models to participate in this Challenge.
The goal is to find whether systems biology based models of human GBM are sufficiently advanced to allow the correct prediction of single agents or combinations that may abrogate tumorogenesis, or significantly delay tumor growth, in vivo. Winning models will be objectively determined, based on a scoring the predictions against held out data on patient derived GBM xenograft models. The best performing teams on this phase will be rewarded with the opportunity to participate in a second phase of this challenge in which the predicted response by the winning teams will be experimentally validated in vivo, through funding generously provided by the National Brain Tumor Society. The NBTS-DREAM Cancer Prediction Challenge organizers will work with the editors of high impact journals to develop a partnership that will allow appropriate dissemination of the winning methodologies and results. The best performing teams in the first phase will be invited to present at the DREAM conference, with their travel expenses covered.
The Whole-Cell Parameter Estimation DREAM Challenge
...